단백질체학 시장 - 세계와 지역 분석 : 오퍼링별, 기술별, 용도별, 최종사용자별, 지역별 - 분석과 예측(2025-2035년)

This report can be delivered within 1 working day.

Global Proteomics Market: Industry Overview

The global proteomics market was valued at approximately $29.60 billion in 2025 and is projected to grow $96.28 billion by 2035, at a CAGR of around 12.52%. The global proteomics market is witnessing accelerated growth driven by the rising prevalence of chronic and neurodegenerative diseases, continuous technological advancements, and the increasing demand for personalized medicine. Proteomics has emerged as a transformative field, enabling in-depth analysis of protein structures, functions, and interactions, which are critical for understanding disease mechanisms and developing targeted therapies. The integration of artificial intelligence, machine learning, and multi-omics platforms is revolutionizing the proteomics workflow, from biomarker discovery to clinical translation, by enabling faster, more accurate, and cost-effective analyses. AI-enabled systems are streamlining data interpretation, uncovering complex protein interaction networks, and facilitating early disease detection through predictive modeling.

Moreover, autonomous discovery platforms and generative AI tools are empowering researchers to perform iterative design, test, and optimize cycles with minimal human intervention, accelerating drug discovery and diagnostics. Pharmaceutical, biotechnology, and contract research organizations are increasingly collaborating with AI-driven startups and technology providers to enhance scalability, improve data integration, and enable precision-driven insights. Strategic partnerships, funding initiatives, and mergers are strengthening the commercialization of advanced proteomic platforms, while cloud-based and on-premise solutions are expanding accessibility across research and clinical settings. Collectively, these factors are reshaping the global proteomics landscape, improving research productivity, and positioning the market for sustained long-term growth.

Global Proteomics Market Lifecycle Stage

The global proteomics market currently stands at the growth and acceleration stage of its lifecycle, transitioning from early adoption toward broader market maturity. Over the past decade, the field has evolved from academic and exploratory research into a strategically critical component of precision medicine, clinical diagnostics, and drug discovery. This shift has been fueled by rapid advancements in mass spectrometry, liquid chromatography, and affinity-based proteomic platforms, alongside the integration of artificial intelligence, machine learning, and multi-omics analytics.

The expansion of the global proteomics market is underpinned by a robust convergence of technological innovation and clinical utility. Continuous improvements in data-independent acquisition (DIA) methods, single-cell and spatial proteomics, and bioinformatics pipelines are enabling high-throughput, high-sensitivity protein profiling. At the same time, commercial players are scaling platform accessibility through automation, cloud-enabled analytics, and service-based delivery models. These trends indicate strong forward momentum as proteomics moves beyond research applications into clinical and translational domains.

While the market exhibits high innovation intensity, its penetration remains uneven across regions and end-user segments. Developed markets in North America and Europe demonstrate near-mainstream adoption within pharma, biotech, and academic research ecosystems. Conversely, adoption in emerging regions is still in its early growth phase, constrained by high capital costs, infrastructure gaps, and limited skilled personnel. This bifurcation positions the market globally within a mid-to-late growth phase, with significant opportunities for expansion through affordable instrumentation, service partnerships, and decentralized proteomic networks.

In summary, the global proteomics market is in a dynamic growth stage, characterized by technological disruption, capital inflows, and expanding end-user adoption. Over the next few years, the industry is expected to move toward early maturity, with broader clinical integration, standardization of workflows, and consolidation among technology providers.

Market Segmentation:

Segmentation 1: By Offering

• Sample Preparation
• Proteomics Technologies
  • Reagents and Consumables
  • Instruments
  • Software
• Proteomics Services

Proteomics technologies segment is expected to account for the largest share of the global proteomics market. This can be attributed to the widespread adoption of advanced analytical platforms, including mass spectrometry, chromatography systems, and specialized software, which are fundamental to conducting high-throughput and high-resolution proteomic analyses. The continuous innovation in instrumentation, growing demand for platform-specific reagents, and increasing integration of AI and cloud-based tools have further strengthened the dominance of this segment. Additionally, the high capital investment associated with proteomic technologies contributes significantly to overall market value.

Segmentation 2: By Technology

• Mass Spectrometry-Based Proteomics
• Chromatography-Based Proteomics
• Protein Microarrays
• Single-Cell Proteomics
• NGS-Based Proteomics
• Others

Based on technology, mass spectrometry-based proteomics is expected to dominate the global proteomics market in 2024. This is primarily due to its unmatched sensitivity, accuracy, and versatility in identifying and quantifying proteins across diverse biological samples. Mass spectrometry has become the gold standard in proteomic research owing to its ability to support both discovery and targeted workflows, detect post-translational modifications, and handle complex sample matrices. Its integration into clinical and translational research has further expanded its adoption across pharmaceutical, academic, and diagnostic settings.

Segmentation 3: By Application

• Biomarker Discovery and Validation
• Proteome Profiling and Mapping
• Drug Discovery and Development
  • Discovery
  • Preclinical
  • Clinical
• Companion Diagnostics
• Protein-Protein Interactions

In 2024, biomarker discovery and validation segment is projected to hold the largest share of the global proteomics market. This dominance is driven by its wide usage across multiple therapeutic areas, integral to precision medicine, and heavily funded for its role in early-stage research, diagnostics, and drug development. Its broad applicability and reliance on diverse proteomics technologies make it the most in-demand application

Segmentation 4: By End User

• Academic and Research Institutions
• Pharmaceutical and Biotechnology Companies
• Clinical Diagnostic Laboratory & Hospitals
• Contract Research Organizations

Based on end-user segmentation, academic and research institutions are expected to account for the largest share of the global proteomics market in 2024. This is primarily driven by the high volume of basic and translational research activities conducted in universities, government-funded laboratories, and public research centers. These institutions are at the forefront of exploring novel proteomic methodologies, biomarker discovery, and systems biology, often supported by significant public and private funding. Additionally, the availability of advanced infrastructure, collaborations with industry players, and a strong focus on innovation have positioned academic and research institutions as key drivers of proteomics adoption globally.

Segmentation 5: By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Based on region, North America is expected to hold the largest share of the global proteomics market in 2024, accounting for 44.69%. This dominance is attributed to the region's well-established research infrastructure, strong presence of key market players, high investment in life sciences R&D, and widespread adoption of advanced proteomic technologies in both academic and clinical settings. Meanwhile, Asia-Pacific is projected to be the fastest-growing region during the forecast period (2025-2035), with a CAGR of 13.86%, driven by increasing government funding for biomedical research, rapid expansion of healthcare infrastructure, growing focus on precision medicine, and a rising number of collaborations between global companies and regional research institutions.

Demand - Drivers and Limitations

Demand Drivers for the Global Proteomics Market:

• Rising Prevalence of Chronic Diseases
• Continuous Technological Advancements
• Increasing Demand for Personalized Medicine

Limitations for the Global Proteomics Market:

• High Costs of Acquisition Hindering the Adoption of Proteomics Technologies
• Shortage of Skilled Professionals

How can this report add value to an organization?

Product/Innovation: This report enables organizations to identify high-value opportunities in the global proteomics market. It guides R&D investment strategies, technology adoption, and pipeline optimization, helping companies prioritize initiatives that accelerate biomarker discovery, disease diagnostics, and therapeutic development. By highlighting emerging technologies, strategic collaborations, and platform scalability, this report helps organizations strengthen their competitive positioning and capitalize on the rapid expansion of proteomics across research, clinical, and pharmaceutical applications.

Growth/Marketing: The report delivers in-depth insights into regional adoption trends, emerging markets, and partnership opportunities, supporting strategic market entry and commercialization planning. It enables companies to identify growth potential across offering, technology, application, and end-user segments. By understanding regional R&D investments, regulatory frameworks, and technology adoption rates, organizations can refine marketing, licensing, and collaboration strategies, maximize visibility, and increase return on investment in a competitive global landscape.

Competitive: This report provides comprehensive company profiling, competitive benchmarking, highlighting strategic collaborations, funding activities, mergers, acquisitions, and technology adoption trends. Stakeholders gain a clear understanding of competitor focus areas, R&D priorities, and market positioning. This intelligence allows organizations to identify gaps, anticipate market shifts, and formulate strategies to differentiate themselves, optimize market entry, and maintain leadership in the proteomics ecosystem.

Key Market Players and Competitive Landscape

The global proteomics market is characterized by a highly competitive and evolving landscape, with participation from both well-established and emerging start-up companies. The key players include leading providers of life science instruments, consumables, and bioinformatics solutions offering advanced technologies such as mass spectrometry, protein microarrays, chromatography systems, and data analysis platforms as well as service providers. Key players include:

• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Bruker Corporation
• Carterra, Inc.
• Danaher Corporation
• DiaSorin S.P.A.
• Erisyon Inc.
• Illumina, Inc.
• RareCyte Inc.
• Quanterix Corporation
• Quantum-Si Incorporated
• Shimadzu Corporation
• Standard BioTools Inc.
• Thermo Fisher Scientific Inc.
• Waters Corporation

Competitive benchmarking highlights mergers and acquisitions, funding activities, licensing deals, and collaborations with pharmaceutical organizations, reflecting the growing emphasis on innovation and speed-to-market. Companies are evaluated based on market presence, technological capabilities, strategic initiatives, and product portfolios. Detailed company profiles cover target end users, technological focus areas, and expert analyst perspectives, providing stakeholders with actionable insights into investment opportunities, market positioning, and strategic growth pathways. This intelligence enables organizations to effectively align their R&D and commercialization strategies with emerging market dynamics of the global proteomics market.

Table of Contents

Executive Summary

Scope and Definition

1 Market: Industry Outlook

• 1.1 Market Overview and Ecosystem
• 1.2 Comparative Advantages and Disadvantages of Proteomics Over Other Omics
• 1.3 Supply Chain Analysis
• 1.4 Market Dynamics
  • 1.4.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
• 1.5 Trends
  • 1.5.1 Increasing Automation for End-to-End Proteomics Workflow
  • 1.5.2 Growing Proteomics Research to Identify Disease Biomarkers
  • 1.5.3 Significant Number of Collaborations among Market Players
• 1.6 Market Dynamics
  • 1.6.1 Market Drivers
    • 1.6.1.1 Rising Prevalence of Chronic Diseases
    • 1.6.1.2 Continuous Technological Advancements
    • 1.6.1.3 Increasing Demand for Personalized Medicine
  • 1.6.2 Market Challenges
    • 1.6.2.1 High Costs of Acquisition Hindering the Adoption of Proteomics Technologies
    • 1.6.2.2 Shortage of Skilled Professionals
  • 1.6.3 Business Strategies
    • 1.6.3.1 Key Product Launch/Expansion
  • 1.6.4 Corporate Strategies
    • 1.6.4.1 Key Partnerships
    • 1.6.4.2 Key Funding and Grants
    • 1.6.4.3 Key Merger and Acquisitions
  • 1.6.5 Market Opportunities
    • 1.6.5.1 Expanding Proteomics Market in Emerging Regions through Affordable Technologies
• 1.7 Regulatory Landscape/Compliance
  • 1.7.1 U.S.
    • 1.7.1.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices
    • 1.7.1.2 Regulatory Requirements for Research Use Only (RUO) Products
    • 1.7.1.3 Requirements under the Clinical Laboratory Improvement Amendments (CLIA) for Clinical Proteomics Labs
  • 1.7.2 Europe
    • 1.7.2.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices
      • 1.7.2.1.1 EU Medical Device Regulation
      • 1.7.2.1.2 EU In Vitro Diagnostic Regulation
      • 1.7.2.1.3 Regulatory Requirements for Clinical Proteomics Labs in the EU
  • 1.7.3 Rest-of-the-World
    • 1.7.3.1 China
      • 1.7.3.1.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices
    • 1.7.3.2 Japan
      • 1.7.3.2.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices
    • 1.7.3.3 Brazil
      • 1.7.3.3.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices
      • 1.7.3.3.2 Regulatory Requirements for Clinical Proteomics Labs in Brazil
• 1.8 Patent Analysis
  • 1.8.1 Patent Analysis (by Year)
  • 1.8.2 Patent Analysis (by Country)
• 1.9 Product Benchmarking

2 Offering

• 2.1 Offering Summary
• 2.2 Global Proteomics Market (by Offering)
  • 2.2.1 Sample Preparation
  • 2.2.2 Proteomics Technologies
    • 2.2.2.1 Reagents and Consumables
      • 2.2.2.1.1 MS-Based Reagents
      • 2.2.2.1.2 Chromatography-Based Reagents
      • 2.2.2.1.3 Protein Microarray Reagents
      • 2.2.2.1.4 Single-Cell Analysis Reagents
      • 2.2.2.1.5 NGS-Based Reagents
      • 2.2.2.1.6 Other Reagents
    • 2.2.2.2 Instruments
      • 2.2.2.2.1 Mass Spectrometers
      • 2.2.2.2.2 Chromatography Systems
      • 2.2.2.2.3 Protein Microarrays
      • 2.2.2.2.4 Single-Cell Analysis Instruments
      • 2.2.2.2.5 NGS Instruments
      • 2.2.2.2.6 Other Instruments
    • 2.2.2.3 Software
      • 2.2.2.3.1 AI-Based Proteomics Analysis Tools
      • 2.2.2.3.2 Spatial Proteomics Data Analytic Software
      • 2.2.2.3.3 Cloud-Based Platforms
  • 2.2.3 Proteomics Services

3 Application

• 3.1 Application Summary
• 3.2 Global Proteomics Market (by Application)
  • 3.2.1 Biomarker Discovery and Validation
  • 3.2.2 Proteome Profiling and Mapping
  • 3.2.3 Drug Discovery and Development
    • 3.2.3.1 Discovery
      • 3.2.3.1.1 Target Identification and Validation
      • 3.2.3.1.2 Others
    • 3.2.3.2 Preclinical
    • 3.2.3.3 Clinical
  • 3.2.4 Companion Diagnostics
  • 3.2.5 Protein-Protein Interactions

4 Technology

• 4.1 Technology Summary
• 4.2 Global Proteomics Market (by Technology)
  • 4.2.1 Mass Spectrometry-Based Proteomics
  • 4.2.2 Chromatography-Based Proteomics
  • 4.2.3 Protein Microarray
  • 4.2.4 Single-Cell Proteomics
  • 4.2.5 NGS-Based Proteomics
  • 4.2.6 Other Technologies

5 End User

• 5.1 End User Summary
• 5.2 Global Proteomics Market (by End User)
  • 5.2.1 Academic and Research Institutions
  • 5.2.2 Pharmaceutical and Biotechnology Companies
  • 5.2.3 Hospitals and Clinical Diagnostics Laboratories
  • 5.2.4 Contract Research Organizations

6 Region

• 6.1 Regional Summary
• 6.2 North America
  • 6.2.1 Regional Overview
  • 6.2.2 Driving Factors for Market Growth
  • 6.2.3 Factors Challenging the Market
  • 6.2.4 By Offering
    • 6.2.4.1 By Proteomics Technologies
  • 6.2.5 By Application
  • 6.2.6 By Country
    • 6.2.6.1 U.S.
      • 6.2.6.1.1 By Offering
      • 6.2.6.1.2 Application
    • 6.2.6.2 Canada
      • 6.2.6.2.1 By Offering
      • 6.2.6.2.2 By Application
• 6.3 Europe
  • 6.3.1 Regional Overview
  • 6.3.2 Driving Factors for Market Growth
  • 6.3.3 Factors Challenging the Market
  • 6.3.4 By Offering
    • 6.3.4.1 By Proteomics Technologies
  • 6.3.5 By Application
  • 6.3.6 By Country
    • 6.3.6.1 U.K.
      • 6.3.6.1.1 By Offering
      • 6.3.6.1.2 By Application
    • 6.3.6.2 Germany
      • 6.3.6.2.1 By Offering
      • 6.3.6.2.2 By Application
    • 6.3.6.3 France
      • 6.3.6.3.1 By Offering
      • 6.3.6.3.2 By Application
    • 6.3.6.4 Italy
      • 6.3.6.4.1 By Offering
      • 6.3.6.4.2 By Application
    • 6.3.6.5 Spain
      • 6.3.6.5.1 By Offering
      • 6.3.6.5.2 By Application
    • 6.3.6.6 Rest-of-Europe
      • 6.3.6.6.1 By Offering
      • 6.3.6.6.2 By Application
• 6.4 Asia-Pacific
  • 6.4.1 Regional Overview
  • 6.4.2 Driving Factors for Market Growth
  • 6.4.3 Factors Challenging the Market
  • 6.4.4 By Offering
    • 6.4.4.1 By Proteomics Technologies
  • 6.4.5 By Application
  • 6.4.6 By Country
    • 6.4.6.1 Japan
      • 6.4.6.1.1 By Offering
      • 6.4.6.1.2 By Application
    • 6.4.6.2 China
      • 6.4.6.2.1 By Offering
      • 6.4.6.2.2 Application
    • 6.4.6.3 India
      • 6.4.6.3.1 By Offering
      • 6.4.6.3.2 By Application
    • 6.4.6.4 Australia
      • 6.4.6.4.1 By Offering
      • 6.4.6.4.2 By Application
    • 6.4.6.5 South Korea
      • 6.4.6.5.1 By Offering
      • 6.4.6.5.2 By Application
    • 6.4.6.6 Rest-of-Asia-Pacific
      • 6.4.6.6.1 By Offering
      • 6.4.6.6.2 By Application
• 6.5 Latin America
  • 6.5.1 Regional Overview
  • 6.5.2 Driving Factors for Market Growth
  • 6.5.3 Factors Challenging the Market
  • 6.5.4 By Offering
    • 6.5.4.1 By Proteomics Technologies
  • 6.5.5 By Application
  • 6.5.6 By Country
    • 6.5.6.1 Brazil
      • 6.5.6.1.1 By Offering
      • 6.5.6.1.2 By Application
    • 6.5.6.2 Mexico
      • 6.5.6.2.1 By Offering
      • 6.5.6.2.2 By Application
    • 6.5.6.3 Rest-of-Latin America
      • 6.5.6.3.1 By Offering
      • 6.5.6.3.2 By Application
• 6.6 Middle East and Africa
  • 6.6.1 Regional Overview
  • 6.6.2 Driving Factors for Market Growth
  • 6.6.3 Factors Challenging the Market
  • 6.6.4 By Offering
    • 6.6.4.1 By Proteomics Technologies
  • 6.6.5 By Application

7 Markets - Competitive Benchmarking & Company Profiles

• 7.1 Company Profiles
  • 7.1.1 Agilent Technologies, Inc.
    • 7.1.1.1 Overview
    • 7.1.1.2 Top Products/Product Portfolio
    • 7.1.1.3 Top Competitors
    • 7.1.1.4 Target Customers
    • 7.1.1.5 Key Personal
    • 7.1.1.6 Analyst View
  • 7.1.2 Becton, Dickinson and Company
    • 7.1.2.1 Overview
    • 7.1.2.2 Top Products/Product Portfolio
    • 7.1.2.3 Top Competitors
    • 7.1.2.4 Target Customers
    • 7.1.2.5 Key Personal
    • 7.1.2.6 Analyst View
  • 7.1.3 Bio-Rad Laboratories, Inc.
    • 7.1.3.1 Overview
    • 7.1.3.2 Top Products/Product Portfolio
    • 7.1.3.3 Top Competitors
    • 7.1.3.4 Target Customers
    • 7.1.3.5 Key Personal
    • 7.1.3.6 Analyst View
  • 7.1.4 Bruker Corporation
    • 7.1.4.1 Overview
    • 7.1.4.2 Top Products/Product Portfolio
    • 7.1.4.3 Top Competitors
    • 7.1.4.4 Target Customers
    • 7.1.4.5 Key Personal
    • 7.1.4.6 Analyst View
  • 7.1.5 Carterra, Inc.
    • 7.1.5.1 Overview
    • 7.1.5.2 Top Products/Product Portfolio
    • 7.1.5.3 Top Competitors
    • 7.1.5.4 Target Customers
    • 7.1.5.5 Key Personal
    • 7.1.5.6 Analyst View
  • 7.1.6 Danaher Corporation
    • 7.1.6.1 Overview
    • 7.1.6.2 Top Products/Product Portfolio
    • 7.1.6.3 Top Competitors
    • 7.1.6.4 Target Customers
    • 7.1.6.5 Key Personal
    • 7.1.6.6 Analyst View
  • 7.1.7 DiaSorin S.P.A.
    • 7.1.7.1 Overview
    • 7.1.7.2 Top Products/Product Portfolio
    • 7.1.7.3 Top Competitors
    • 7.1.7.4 Target Customers
    • 7.1.7.5 Key Personal
    • 7.1.7.6 Analyst View
  • 7.1.8 Erisyon Inc.
    • 7.1.8.1 Overview
    • 7.1.8.2 Top Products/Product Portfolio
    • 7.1.8.3 Top Competitors
    • 7.1.8.4 Target Customers
    • 7.1.8.5 Key Personal
    • 7.1.8.6 Analyst View
    • 7.1.8.7 Market Share, 2023
  • 7.1.9 Illumina, Inc.
    • 7.1.9.1 Overview
    • 7.1.9.2 Top Products/Product Portfolio
    • 7.1.9.3 Top Competitors
    • 7.1.9.4 Target Customers
    • 7.1.9.5 Key Personal
    • 7.1.9.6 Analyst View
  • 7.1.10 RareCyte Inc.
    • 7.1.10.1 Overview
    • 7.1.10.2 Top Products/Product Portfolio
    • 7.1.10.3 Top Competitors
    • 7.1.10.4 Target Customers
    • 7.1.10.5 Key Personal
    • 7.1.10.6 Analyst View
  • 7.1.11 Quanterix Corporation
    • 7.1.11.1 Overview
    • 7.1.11.2 Top Competitors
    • 7.1.11.3 Target Customers
    • 7.1.11.4 Key Personal
    • 7.1.11.5 Analyst View
    • 7.1.11.6 Market Share, 2023
  • 7.1.12 Quantum-Si Incorporated
    • 7.1.12.1 Overview
    • 7.1.12.2 Top Products/Product Portfolio
    • 7.1.12.3 Top Competitors
    • 7.1.12.4 Target Customers
    • 7.1.12.5 Key Personal
    • 7.1.12.6 Analyst View
  • 7.1.13 Shimadzu Corporation
    • 7.1.13.1 Overview
    • 7.1.13.2 Top Products/Product Portfolio
    • 7.1.13.3 Top Competitors
    • 7.1.13.4 Target Customers
    • 7.1.13.5 Key Personal
    • 7.1.13.6 Analyst View
  • 7.1.14 Standard BioTools Inc.
    • 7.1.14.1 Overview
    • 7.1.14.2 Top Products/Product Portfolio
    • 7.1.14.3 Top Competitors
    • 7.1.14.4 Target Customers
    • 7.1.14.5 Key Personal
    • 7.1.14.6 Analyst View
  • 7.1.15 Thermo Fisher Scientific Inc.
    • 7.1.15.1 Overview
    • 7.1.15.2 Top Products/Product Portfolio
    • 7.1.15.3 Top Competitors
    • 7.1.15.4 Target Customers
    • 7.1.15.5 Key Personal
    • 7.1.15.6 Analyst View
  • 7.1.16 Waters Corporation
    • 7.1.16.1 Overview
    • 7.1.16.2 Top Products/Product Portfolio
    • 7.1.16.3 Top Competitors
    • 7.1.16.4 Target Customers
    • 7.1.16.5 Key Personal
    • 7.1.16.6 Analyst View

8 Research Methodology

• 8.1 Data Sources
  • 8.1.1 Primary Data Sources
  • 8.1.2 Secondary Data Sources
  • 8.1.3 Data Triangulation
• 8.2 Market Estimation and Forecast